Login
Navigate Fool.com
Will LLY beat
the market?

Eli Lilly & Co.

NYSE: LLY

Community Rating: 3 Stars: Appealing

59.73 -0.23 (-0.38%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $59.73
Previous Close $59.96
Daily Range $59.63 - $59.98
52-Week Range $47.53 - $60.46
Market Cap $66.9B
P/E Ratio 13.88
Dividend (Yield) $1.96 (3.3%)
Ex-Dividend Date
Dividend Pay Date
02/12/14
03/10/14
Volume 370,294
Average Daily Volume 4,893,561
Current FY EPS $2.80

How do you think LLY
will perform against the market?

Top LLY Bull/Bear Pitches

 

cibient (14.8)
Submitted May 26, 2011

5% divy, sustainable payout ratio (45% according to Yahoo! Finance), MFI stats from <a href="http://MagicDiligence.com">MagicDiligence.com</a>:<br /><br />Results for ticker 'LLY' (Eli Lilly and Compa … More

0 Replies Reply Report this Post
 

bobbyvee (< 20)
Submitted March 7, 2009

Pharaceuticals will suffer under this administration's plan for universal care

4 Replies Reply Report this Post

News & Commentary Rss Feed

The Biggest Biotech Wins of the Week

Find out which biotech and pharmaceutical companies posted the best clinical results for the week ending April 11.

Insider Stock Trading: Carl Icahn Buys Shares of Navistar International

Plus, purchases at Cerulean Pharmaceuticals, Alliqua, and Nature's Sunshine Products.

Eli Lilly's $3 Billion Mistake

A jury rules against Eli Lilly and partner Takeda with steep punative penalties

MannKind's Overly-Optimisitic Investors

Despite issues, over half of investors in a Motley Fool poll thought MannKind's inhaled insulin, Afrezza, would be approved this week.

Healthcare Stocks Posting Moderate Gains; Lilly, Partner File NDA for Combination Tablet for Diabete

Healthcare Stocks Posting Moderate Gains; Lilly, Partner File NDA for Combination Tablet for Diabetes

Sector Update: Healthcare

Is Teva Pharmaceutical Industries Ltd. Destined for Greatness?

Let's see what the numbers say about Teva (TEVA).

Stock Upgrades: Eli Lilly Coming Up Roses

Wall Street ratings agencies set the tone for today's stock market.

Can This Drug Be a Game Changer for Eli Lilly?

Eli Lilly's experimental breast cancer drug is reporting strong results in an early-stage trial. Here is what you need to know going forward.

2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals

Two clinical-stage cancer companies could provide market-beating returns for risk-tolerant investors.

See More LLY News...

Sector

Healthcare

Industry

Drugs

Eli Lilly & Co. (LLY) Description

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website: http://www.lilly.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks